Vericel Corporation (VCEL:NASDAQ) closed at $42.53 on October 23, 2026, down 1.02% on the day. The stock trades 13.8% below its 52-week high of $49.32 and 46.9% above its 52-week low of $28.95. Over the past year, it gained 17.1%. Vericel Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 23, 2025, VCEL closed higher on 128 days (51%). Its best day was November 25, 2025 (+9.41%) and its worst was April 29, 2026 (-6.23%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 2 times.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Find more stocks like VCEL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.